Partnering with Patients: The Cornerstone of Cancer Care and Research

1 May 2023
16 May 2023

Read the latest in cancer care and research

At Wiley, we make oncology research more accessible improving patient care around the world. We help researchers advance the field by making life-changing research available to scientists, policy-makers, patients and those teaching the next generation of clinicians. Discover some of the latest advancements in the field collected into one themed issue inspired by the theme of this year's American Society of Clinical Oncology's Annual Meeting: Partnering with Patients: The Cornerstone of Cancer Care and Research.


Partnering with Patients: The Cornerstone of Cancer Care and Research

Melanoma/Skin Cancer

Open Access

EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma

EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma

Graphical Highlights:

1. EEF2K silencing attenuates melanoma progression.

2. EEF2K mediates melanoma progression through p-STAT3/SPP1 axis.

3. Cytarabine, a potential clinically applicable EEF2K inhibitor, synergises with BET inhibitors in melanoma treatment.

Open Access

Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype

Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype

  • Biomarker candidates were identified through unsupervised data mining of melanoma versus benign nevi or healthy skin transcriptomes.
  • Droplet digital PCR (ddPCR) assays were developed for circulating cell-free RNA (cfRNA) quantification.
  • KPNA2, DTL, BACE2 and DTYMK cfRNA demonstrated high diagnostic accuracy in melanoma.
  • High baseline cfRNA levels were associated with significantly shorter progression-free survival.
  • cfRNA copies significantly increased during therapy in non-responders regardless of therapy and mutational subtypes.

Open Access

Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103+DC cells

  • First Published: 05 March 2023
Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103+DC cells

In the 7,12-dimethylbenzoanthracene/tetradecylphorbol-13-acetate two-stage skin cancer induction model, interleukin weakened the expression of CD40/CCR7 and the secretion of C-X-C motif chemokine ligand 9/CXCL10 in CD103+DCs through single immunoglobulin interleukin-1-related receptor-activated protein kinase-Akt signal axis, which leads to the suppression the function of CD8+T cells and accelerating the growth of tumor.

Open Access

Circular RNAs: Biomarkers of cancer

Circular RNAs: Biomarkers of cancer

This study demonstrates that circular RNAs (circRNAs) have great potential as biomarkers for cancer diagnosis and prognosis, which is highlighted by their detectability in tissues and fluid biopsy samples. CircRNAs may act as biomarkers in cancers including glioma, bladder cancer, breast cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer, lung cancer, kidney cancer, pancreatic cancer, and leukemia.

Pediatric Oncology

Open Access

Spontaneous xenogeneic GvHD in Wilms' tumor Patient-Derived xenograft models and potential solutions

Spontaneous xenogeneic GvHD in Wilms' tumor Patient-Derived xenograft models and potential solutions

Three consecutive generations of NOG mice bearing Wilms tumor patient-derived xenografts from a single donor showed different degrees of immunoinflammatory symptoms. Histopathologic evaluations of the xenografts and parental tumor showed lymphoid infiltrates and human-originated CD3 and CD8 positive cells in the tissue blocks, while no lymphoproliferative disorder was evident (suggestive of a lymphodominant tumor graft). In the absence of microbial infection and lymphoproliferative disorder, the syndrome was suggestive of xenogeneic graft-versus-host disease.

Open Access

Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology

Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology

Metastatic Epithelioid Sarcoma has a largely unmet clinical need in pediatrics and young adults. To identify potential targets for inhibition we conducted next generation DNA exome and RNA deep sequencing and chemical screens in EPS patient samples and cell lines. We uncovered distinguishing features of the two subtypes of EPS, distal and proximal.

Open Access

FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression

FABP4 deactivates NF-κB-IL1α pathway by ubiquitinating ATPB in tumor-associated macrophages and promotes neuroblastoma progression

  1. FABP4 in macrophages expression is correlated with advanced clinical stages and unfavorable histology of neuroblastoma.

  2. FABP4 in macrophages increases migration, invasion, and tumor growth of neuroblastoma cells.

  3. FABP4 in macrophages may promote proliferation and migration phenotypes in neuroblastoma cells through deactivating NF-κB-IL1α pathway by ubiquitinating ATPB.

Open Access

Dosimetric evaluation of adult and paediatric brain tumours planned using mask-based cobalt-60 fractionated stereotactic radiotherapy compared to linear accelerator-based volumetric modulated arc therapy

Dosimetric evaluation of adult and paediatric brain tumours planned using mask-based cobalt-60 fractionated stereotactic radiotherapy compared to linear accelerator-based volumetric modulated arc therapy

In this comparative dosimetry study, fractionated cobalt-60 radiosurgery plans (top panels) achieved equivalent target coverage but improved conformity and organ-at-risk sparing as compared to VMAT plans (bottom panels). Fractionated radiosurgery may be considered for future prospective study as a highly focused modality for photon radiation of intracranial tumours.

Open Access

Promoting the application of pediatric radiomics via an integrated medical engineering approach

Promoting the application of pediatric radiomics via an integrated medical engineering approach

Radiomics is widely used in adult tumors but has been rarely applied to the field of pediatrics. Promoting the application of radiomics in pediatric diseases, especially in the early diagnosis and stratified treatment of tumors, is of great value to the realization of the WHO 2030 “Global Initiative for Childhood Cancer.” This paper discusses the general characteristics of radiomics, the particularity of its application to pediatric diseases, and the current status and prospects of pediatric radiomics.